Clinical  ||| S:0 E:9 ||| JJ
efficacy  ||| S:9 E:18 ||| NN
of  ||| S:18 E:21 ||| IN
Avène  ||| S:21 E:27 ||| NNP
hydrotherapy  ||| S:27 E:40 ||| VBD
measured  ||| S:40 E:49 ||| VBN
in  ||| S:49 E:52 ||| IN
a  ||| S:52 E:54 ||| DT
large  ||| S:54 E:60 ||| JJ
cohort  ||| S:60 E:67 ||| NN
of  ||| S:67 E:70 ||| IN
more  ||| S:70 E:75 ||| JJR
than  ||| S:75 E:80 ||| IN
10,000  ||| S:80 E:87 ||| CD
atopic  ||| S:87 E:94 ||| NNS
or  ||| S:94 E:97 ||| CC
psoriatic  ||| S:97 E:107 ||| FW
patients  ||| S:107 E:116 ||| FW
Atopic  ||| S:116 E:123 ||| FW
dermatitis  ||| S:123 E:134 ||| FW
( ||| S:134 E:135 ||| -LRB-
AD ||| S:135 E:137 ||| NNP
)  ||| S:137 E:139 ||| -RRB-
and  ||| S:139 E:143 ||| CC
psoriasis  ||| S:143 E:153 ||| NNS
are  ||| S:153 E:157 ||| VBP
chronic  ||| S:157 E:165 ||| JJ
skin  ||| S:165 E:170 ||| NN
conditions ||| S:170 E:180 ||| NNS
.  ||| S:180 E:182 ||| .
Local  ||| S:182 E:188 ||| JJ
or  ||| S:188 E:191 ||| CC
systemic  ||| S:191 E:200 ||| JJ
treatments  ||| S:200 E:211 ||| NNS
are  ||| S:211 E:215 ||| VBP
effective ||| S:215 E:224 ||| JJ
,  ||| S:224 E:226 ||| ,
but  ||| S:226 E:230 ||| CC
their  ||| S:230 E:236 ||| PRP$
effects  ||| S:236 E:244 ||| NNS
are  ||| S:244 E:248 ||| VBP
transient ||| S:248 E:257 ||| VBN
.  ||| S:257 E:259 ||| .
Hydrotherapy ||| S:259 E:271 ||| NNP
,  ||| S:271 E:273 ||| ,
used  ||| S:273 E:278 ||| VBN
alone  ||| S:278 E:284 ||| RB
or  ||| S:284 E:287 ||| CC
in  ||| S:287 E:290 ||| IN
combination  ||| S:290 E:302 ||| NN
with  ||| S:302 E:307 ||| IN
other  ||| S:307 E:313 ||| JJ
treatments ||| S:313 E:323 ||| NNS
,  ||| S:323 E:325 ||| ,
could  ||| S:325 E:331 ||| MD
be  ||| S:331 E:334 ||| VB
considered  ||| S:334 E:345 ||| VBN
as  ||| S:345 E:348 ||| IN
one  ||| S:348 E:352 ||| CD
form  ||| S:352 E:357 ||| NN
of  ||| S:357 E:360 ||| IN
care  ||| S:360 E:365 ||| NN
in  ||| S:365 E:368 ||| IN
providing  ||| S:368 E:378 ||| VBG
effective  ||| S:378 E:388 ||| JJ
management  ||| S:388 E:399 ||| NN
of  ||| S:399 E:402 ||| IN
these  ||| S:402 E:408 ||| DT
dermatoses ||| S:408 E:418 ||| NN
.  ||| S:418 E:420 ||| .
The  ||| S:420 E:424 ||| DT
objective  ||| S:424 E:434 ||| NN
of  ||| S:434 E:437 ||| IN
this  ||| S:437 E:442 ||| DT
observational  ||| S:442 E:456 ||| JJ
study  ||| S:456 E:462 ||| NN
was  ||| S:462 E:466 ||| VBD
to  ||| S:466 E:469 ||| TO
evaluate  ||| S:469 E:478 ||| VB
the  ||| S:478 E:482 ||| DT
benefit  ||| S:482 E:490 ||| NN
of  ||| S:490 E:493 ||| IN
a  ||| S:493 E:495 ||| DT
3-week  ||| S:495 E:502 ||| JJ
treatment  ||| S:502 E:512 ||| NN
at  ||| S:512 E:515 ||| IN
Avène  ||| S:515 E:521 ||| NNP
Hydrotherapy  ||| S:521 E:534 ||| NNP
Centre  ||| S:534 E:541 ||| NNP
in  ||| S:541 E:544 ||| IN
a  ||| S:544 E:546 ||| DT
very  ||| S:546 E:551 ||| RB
large  ||| S:551 E:557 ||| JJ
cohort  ||| S:557 E:564 ||| NN
of  ||| S:564 E:567 ||| IN
patients  ||| S:567 E:576 ||| NNS
suffering  ||| S:576 E:586 ||| VBG
from  ||| S:586 E:591 ||| IN
atopic  ||| S:591 E:598 ||| JJ
dermatitis  ||| S:598 E:609 ||| NN
and  ||| S:609 E:613 ||| CC
psoriasis  ||| S:613 E:623 ||| NNS
and  ||| S:623 E:627 ||| CC
to  ||| S:627 E:630 ||| TO
assess  ||| S:630 E:637 ||| VB
the  ||| S:637 E:641 ||| DT
treatment  ||| S:641 E:651 ||| NN
benefits  ||| S:651 E:660 ||| NNS
on  ||| S:660 E:663 ||| IN
patients  ||| S:663 E:672 ||| NNS
undergoing  ||| S:672 E:683 ||| VBG
hydrotherapy  ||| S:683 E:696 ||| NN
for  ||| S:696 E:700 ||| IN
two  ||| S:700 E:704 ||| CD
consecutive  ||| S:704 E:716 ||| JJ
years ||| S:716 E:721 ||| NNS
.  ||| S:721 E:723 ||| .
This  ||| S:723 E:728 ||| DT
8-year  ||| S:728 E:735 ||| JJ
observational  ||| S:735 E:749 ||| JJ
study  ||| S:749 E:755 ||| NN
analysed  ||| S:755 E:764 ||| VBD
14,328  ||| S:764 E:771 ||| CD
records  ||| S:771 E:779 ||| NNS
of  ||| S:779 E:782 ||| IN
patients  ||| S:782 E:791 ||| NNS
having  ||| S:791 E:798 ||| VBG
a  ||| S:798 E:800 ||| DT
dermatological  ||| S:800 E:815 ||| JJ
disease  ||| S:815 E:823 ||| NN
and  ||| S:823 E:827 ||| CC
who  ||| S:827 E:831 ||| WP
came  ||| S:831 E:836 ||| VBD
to  ||| S:836 E:839 ||| TO
Avène  ||| S:839 E:845 ||| NNP
Hydrotherapy  ||| S:845 E:858 ||| NNP
Centre  ||| S:858 E:865 ||| NNP
for  ||| S:865 E:869 ||| IN
a  ||| S:869 E:871 ||| DT
3-week  ||| S:871 E:878 ||| JJ
treatment  ||| S:878 E:888 ||| NN
between  ||| S:888 E:896 ||| IN
2001  ||| S:896 E:901 ||| CD
and  ||| S:901 E:905 ||| CC
2009 ||| S:905 E:909 ||| CD
.  ||| S:909 E:911 ||| .
Among  ||| S:911 E:917 ||| IN
them ||| S:917 E:921 ||| PRP
,  ||| S:921 E:923 ||| ,
patients  ||| S:923 E:932 ||| NNS
were  ||| S:932 E:937 ||| VBD
suffering  ||| S:937 E:947 ||| VBG
from  ||| S:947 E:952 ||| IN
atopic  ||| S:952 E:959 ||| JJ
dermatitis  ||| S:959 E:970 ||| NNS
( ||| S:970 E:971 ||| -LRB-
n  ||| S:971 E:973 ||| CD
=  ||| S:973 E:975 ||| SYM
5916 ||| S:975 E:979 ||| CD
)  ||| S:979 E:981 ||| -RRB-
and  ||| S:981 E:985 ||| CC
psoriasis  ||| S:985 E:995 ||| NNS
( ||| S:995 E:996 ||| -LRB-
n  ||| S:996 E:998 ||| CD
=  ||| S:998 E:1000 ||| SYM
4887 ||| S:1000 E:1004 ||| CD
) ||| S:1004 E:1005 ||| -RRB-
.  ||| S:1005 E:1007 ||| .
On  ||| S:1007 E:1010 ||| IN
admission  ||| S:1010 E:1020 ||| NN
on  ||| S:1020 E:1023 ||| IN
D0  ||| S:1023 E:1026 ||| NNP
( ||| S:1026 E:1027 ||| -LRB-
day  ||| S:1027 E:1031 ||| NN
0 ||| S:1031 E:1032 ||| CD
)  ||| S:1032 E:1034 ||| -RRB-
and  ||| S:1034 E:1038 ||| CC
at  ||| S:1038 E:1041 ||| IN
the  ||| S:1041 E:1045 ||| DT
end  ||| S:1045 E:1049 ||| NN
of  ||| S:1049 E:1052 ||| IN
cure  ||| S:1052 E:1057 ||| NN
on  ||| S:1057 E:1060 ||| IN
D18  ||| S:1060 E:1064 ||| NNP
( ||| S:1064 E:1065 ||| -LRB-
day  ||| S:1065 E:1069 ||| NN
18 ||| S:1069 E:1071 ||| CD
) ||| S:1071 E:1072 ||| -RRB-
,  ||| S:1072 E:1074 ||| ,
the  ||| S:1074 E:1078 ||| DT
severity  ||| S:1078 E:1087 ||| NN
of  ||| S:1087 E:1090 ||| IN
AD  ||| S:1090 E:1093 ||| NNP
and  ||| S:1093 E:1097 ||| CC
psoriasis  ||| S:1097 E:1107 ||| NNS
were  ||| S:1107 E:1112 ||| VBD
evaluated  ||| S:1112 E:1122 ||| VBN
by  ||| S:1122 E:1125 ||| IN
SCORing  ||| S:1125 E:1133 ||| NNP
Atopic  ||| S:1133 E:1140 ||| NNP
Dermatitis  ||| S:1140 E:1151 ||| NNP
( ||| S:1151 E:1152 ||| -LRB-
SCORAD ||| S:1152 E:1158 ||| NNP
)  ||| S:1158 E:1160 ||| -RRB-
and  ||| S:1160 E:1164 ||| CC
Psoriasis  ||| S:1164 E:1174 ||| NNP
Area  ||| S:1174 E:1179 ||| NNP
and  ||| S:1179 E:1183 ||| CC
Severity  ||| S:1183 E:1192 ||| NNP
Index  ||| S:1192 E:1198 ||| NNP
( ||| S:1198 E:1199 ||| -LRB-
PASI ||| S:1199 E:1203 ||| NNP
) ||| S:1203 E:1204 ||| -RRB-
,  ||| S:1204 E:1206 ||| ,
respectively ||| S:1206 E:1218 ||| RB
.  ||| S:1218 E:1220 ||| .
In  ||| S:1220 E:1223 ||| IN
order  ||| S:1223 E:1229 ||| NN
to  ||| S:1229 E:1232 ||| TO
assess  ||| S:1232 E:1239 ||| VB
the  ||| S:1239 E:1243 ||| DT
cumulative  ||| S:1243 E:1254 ||| JJ
effect  ||| S:1254 E:1261 ||| NN
of  ||| S:1261 E:1264 ||| IN
the  ||| S:1264 E:1268 ||| DT
hydrotherapy  ||| S:1268 E:1281 ||| JJ
treatment ||| S:1281 E:1290 ||| NN
,  ||| S:1290 E:1292 ||| ,
the  ||| S:1292 E:1296 ||| DT
evolution  ||| S:1296 E:1306 ||| NN
of  ||| S:1306 E:1309 ||| IN
SCORAD  ||| S:1309 E:1316 ||| NNP
or  ||| S:1316 E:1319 ||| CC
PASI  ||| S:1319 E:1324 ||| NNP
of  ||| S:1324 E:1327 ||| IN
patients  ||| S:1327 E:1336 ||| NNS
who  ||| S:1336 E:1340 ||| WP
came  ||| S:1340 E:1345 ||| VBD
2  ||| S:1345 E:1347 ||| CD
years  ||| S:1347 E:1353 ||| NNS
in  ||| S:1353 E:1356 ||| IN
a  ||| S:1356 E:1358 ||| DT
row  ||| S:1358 E:1362 ||| NN
was  ||| S:1362 E:1366 ||| VBD
also  ||| S:1366 E:1371 ||| RB
calculated ||| S:1371 E:1381 ||| VBN
.  ||| S:1381 E:1383 ||| .
A  ||| S:1383 E:1385 ||| DT
significant  ||| S:1385 E:1397 ||| JJ
improvement  ||| S:1397 E:1409 ||| NN
in  ||| S:1409 E:1412 ||| IN
SCORAD  ||| S:1412 E:1419 ||| NNP
was  ||| S:1419 E:1423 ||| VBD
observed  ||| S:1423 E:1432 ||| VBN
between  ||| S:1432 E:1440 ||| IN
D0  ||| S:1440 E:1443 ||| NNP
and  ||| S:1443 E:1447 ||| CC
D18  ||| S:1447 E:1451 ||| NNP
( ||| S:1451 E:1452 ||| -LRB-
-41.6 ||| S:1452 E:1457 ||| NNP
% ||| S:1457 E:1458 ||| NN
)  ||| S:1458 E:1460 ||| -RRB-
( ||| S:1460 E:1461 ||| -LRB-
P  ||| S:1461 E:1463 ||| NNP
< ||| S:1463 E:1465 ||| SYM
0.0001 ||| S:1465 E:1471 ||| NNP
)  ||| S:1471 E:1473 ||| -RRB-
and  ||| S:1473 E:1477 ||| CC
similarly ||| S:1477 E:1486 ||| RB
,  ||| S:1486 E:1488 ||| ,
a  ||| S:1488 E:1490 ||| DT
significant  ||| S:1490 E:1502 ||| JJ
reduction  ||| S:1502 E:1512 ||| NN
in  ||| S:1512 E:1515 ||| IN
PASI  ||| S:1515 E:1520 ||| NNP
was  ||| S:1520 E:1524 ||| VBD
noted  ||| S:1524 E:1530 ||| VBN
between  ||| S:1530 E:1538 ||| IN
D0  ||| S:1538 E:1541 ||| NNP
and  ||| S:1541 E:1545 ||| CC
D18  ||| S:1545 E:1549 ||| NNP
( ||| S:1549 E:1550 ||| -LRB-
-54.4 ||| S:1550 E:1555 ||| NNP
% ||| S:1555 E:1556 ||| NN
)  ||| S:1556 E:1558 ||| -RRB-
( ||| S:1558 E:1559 ||| -LRB-
P  ||| S:1559 E:1561 ||| NNP
< ||| S:1561 E:1563 ||| SYM
0.0001 ||| S:1563 E:1569 ||| NNP
)  ||| S:1569 E:1571 ||| -RRB-
after  ||| S:1571 E:1577 ||| IN
3-weeks  ||| S:1577 E:1585 ||| CD
of  ||| S:1585 E:1588 ||| IN
hydrotherapy ||| S:1588 E:1600 ||| NN
.  ||| S:1600 E:1602 ||| .
PASI  ||| S:1602 E:1607 ||| NNP
50  ||| S:1607 E:1610 ||| CD
and  ||| S:1610 E:1614 ||| CC
PASI  ||| S:1614 E:1619 ||| NNP
75  ||| S:1619 E:1622 ||| CD
were  ||| S:1622 E:1627 ||| VBD
64.3 ||| S:1627 E:1631 ||| CD
%  ||| S:1631 E:1633 ||| NN
and  ||| S:1633 E:1637 ||| CC
19.5 ||| S:1637 E:1641 ||| CD
% ||| S:1641 E:1642 ||| NN
,  ||| S:1642 E:1644 ||| ,
respectively ||| S:1644 E:1656 ||| RB
.  ||| S:1656 E:1658 ||| .
For  ||| S:1658 E:1662 ||| IN
atopic  ||| S:1662 E:1669 ||| JJ
patients  ||| S:1669 E:1678 ||| NNS
( ||| S:1678 E:1679 ||| -LRB-
n  ||| S:1679 E:1681 ||| CD
=  ||| S:1681 E:1683 ||| SYM
1102 ||| S:1683 E:1687 ||| CD
)  ||| S:1687 E:1689 ||| -RRB-
or  ||| S:1689 E:1692 ||| CC
patients  ||| S:1692 E:1701 ||| NNS
suffering  ||| S:1701 E:1711 ||| VBG
from  ||| S:1711 E:1716 ||| IN
psoriasis  ||| S:1716 E:1726 ||| NNS
( ||| S:1726 E:1727 ||| -LRB-
n  ||| S:1727 E:1729 ||| CD
=  ||| S:1729 E:1731 ||| SYM
833 ||| S:1731 E:1734 ||| CD
)  ||| S:1734 E:1736 ||| -RRB-
who  ||| S:1736 E:1740 ||| WP
came  ||| S:1740 E:1745 ||| VBD
for  ||| S:1745 E:1749 ||| IN
two  ||| S:1749 E:1753 ||| CD
consecutive  ||| S:1753 E:1765 ||| JJ
years ||| S:1765 E:1770 ||| NNS
,  ||| S:1770 E:1772 ||| ,
a  ||| S:1772 E:1774 ||| DT
significant  ||| S:1774 E:1786 ||| JJ
SCORAD  ||| S:1786 E:1793 ||| NNP
and  ||| S:1793 E:1797 ||| CC
PASI  ||| S:1797 E:1802 ||| NNP
improvement  ||| S:1802 E:1814 ||| NN
was  ||| S:1814 E:1818 ||| VBD
observed  ||| S:1818 E:1827 ||| VBN
on  ||| S:1827 E:1830 ||| IN
D0  ||| S:1830 E:1833 ||| CD
of  ||| S:1833 E:1836 ||| IN
the  ||| S:1836 E:1840 ||| DT
second  ||| S:1840 E:1847 ||| JJ
year  ||| S:1847 E:1852 ||| NN
when  ||| S:1852 E:1857 ||| WRB
compared  ||| S:1857 E:1866 ||| VBN
with  ||| S:1866 E:1871 ||| IN
D0  ||| S:1871 E:1874 ||| CD
of  ||| S:1874 E:1877 ||| IN
the  ||| S:1877 E:1881 ||| DT
previous  ||| S:1881 E:1890 ||| JJ
year  ||| S:1890 E:1895 ||| NN
( ||| S:1895 E:1896 ||| -LRB-
P  ||| S:1896 E:1898 ||| NNP
< ||| S:1898 E:1900 ||| SYM
0.0001 ||| S:1900 E:1906 ||| NNP
) ||| S:1906 E:1907 ||| -RRB-
.  ||| S:1907 E:1909 ||| .
This  ||| S:1909 E:1914 ||| DT
study  ||| S:1914 E:1920 ||| NN
is  ||| S:1920 E:1923 ||| VBZ
the  ||| S:1923 E:1927 ||| DT
first  ||| S:1927 E:1933 ||| JJ
observational  ||| S:1933 E:1947 ||| JJ
study  ||| S:1947 E:1953 ||| NN
in  ||| S:1953 E:1956 ||| IN
such  ||| S:1956 E:1961 ||| PDT
a  ||| S:1961 E:1963 ||| DT
large  ||| S:1963 E:1969 ||| JJ
cohort  ||| S:1969 E:1976 ||| NNS
demonstrating  ||| S:1976 E:1990 ||| VBG
the  ||| S:1990 E:1994 ||| DT
benefit  ||| S:1994 E:2002 ||| NN
of  ||| S:2002 E:2005 ||| IN
a  ||| S:2005 E:2007 ||| DT
3-week  ||| S:2007 E:2014 ||| JJ
treatment  ||| S:2014 E:2024 ||| NN
at  ||| S:2024 E:2027 ||| IN
the  ||| S:2027 E:2031 ||| DT
Avène  ||| S:2031 E:2037 ||| NNP
Hydrotherapy  ||| S:2037 E:2050 ||| NNP
Centre  ||| S:2050 E:2057 ||| NNP
for  ||| S:2057 E:2061 ||| IN
atopic  ||| S:2061 E:2068 ||| NN
and  ||| S:2068 E:2072 ||| CC
psoriatic  ||| S:2072 E:2082 ||| JJ
patients ||| S:2082 E:2090 ||| NNS
.  ||| S:2090 E:2092 ||| .
